Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.
Plexium has raised $60.1M in total funding. The most recent round was Series C. The last funding was announced in August 2025.
Plexium's investors include RA Capital Management, Lux Capital, CRV, DCVC Bio, TCG Crossover.
Plexium is headquartered in San Diego, United States.
Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.
Plexium is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Plexium — Funding & Investors." VCBacked, August 25, 2025, https://www.vcbacked.co/company/plexium. Accessed October 29, 2026.
VCBacked. (2025). Plexium — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/plexium
{{cite web |title=Plexium — Funding & Investors |url=https://www.vcbacked.co/company/plexium |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated